title: What have we learnt from Vioxx?
authors.affiliation: Department of Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208088, New Haven, CT 06520-8088, USA. harlan.krumholz@yale.edu
authors.forename: Harlan M
authors.initials: HM
authors.lastname: Krumholz
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Ross
authors.forename: Amos H
authors.initials: AH
authors.lastname: Presler
authors.forename: David S
authors.initials: DS
authors.lastname: Egilman
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D035881:Compensation and Redress / Q000331:legislation & jurisprudence*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D007400:Interprofessional Relations; D007783:Lactones / Q000009:adverse effects*; D012307:Risk Factors; D015871:Scientific Misconduct / Q000331:legislation & jurisprudence; D013450:Sulfones / Q000009:adverse effects*; D013997:Time Factors; D006113:United Kingdom; D014481:United States
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib